Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
Abstract We established patient-derived xenografts (PDX) from human primary breast cancers and studied whether stability or progressive events occurred during long-term in vivo passages (up to 4 years) in severely immunodeficient mice. While most PDX showed stable biomarker expression and growth phe...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/59a0895a37d34757859e7e9b853a7ad6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:59a0895a37d34757859e7e9b853a7ad6 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:59a0895a37d34757859e7e9b853a7ad62021-12-02T15:23:03ZEarly stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft10.1038/s41598-021-81085-y2045-2322https://doaj.org/article/59a0895a37d34757859e7e9b853a7ad62021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81085-yhttps://doaj.org/toc/2045-2322Abstract We established patient-derived xenografts (PDX) from human primary breast cancers and studied whether stability or progressive events occurred during long-term in vivo passages (up to 4 years) in severely immunodeficient mice. While most PDX showed stable biomarker expression and growth phenotype, a HER2-positive PDX (PDX-BRB4) originated a subline (out of 6 studied in parallel) that progressively acquired a significantly increased tumor growth rate, resistance to cell senescence of in vitro cultures, increased stem cell marker expression and high lung metastatic ability, along with a strong decrease of BCL2 expression. RNAseq analysis of the progressed subline showed that BCL2 was connected to three main hub genes also down-regulated (CDKN2A, STAT5A and WT1). Gene expression of progressed subline suggested a partial epithelial-to-mesenchymal transition. PDX-BRB4 with its progressed subline is a preclinical model mirroring the clinical paradox of high level-BCL2 as a good prognostic factor in breast cancer. Sequential in vivo passages of PDX-BRB4 chronically treated with trastuzumab developed progressive loss of sensitivity to trastuzumab while HER2 expression and sensitivity to the pan-HER tyrosine kinase inhibitor neratinib were maintained. Long-term PDX studies, even though demanding, can originate new preclinical models, suitable to investigate the mechanisms of breast cancer progression and new therapeutic approaches.Lorena LanduzziArianna PalladiniClaudio CeccarelliSofia AsioliGiordano NicolettiVeronica GiustiFrancesca RuzziMarianna L. IanzanoLaura ScalambraRoberta LarangaTania BalboniMaddalena ArigoniMartina OliveroRaffaele A. CalogeroCarla De GiovanniMassimiliano Dall’OraEnrico Di OtoDonatella SantiniMaria Pia FoschiniMaria Cristina CucchiSimone ZanottiMario TaffurelliPatrizia NanniPier-Luigi LolliniNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-14 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Lorena Landuzzi Arianna Palladini Claudio Ceccarelli Sofia Asioli Giordano Nicoletti Veronica Giusti Francesca Ruzzi Marianna L. Ianzano Laura Scalambra Roberta Laranga Tania Balboni Maddalena Arigoni Martina Olivero Raffaele A. Calogero Carla De Giovanni Massimiliano Dall’Ora Enrico Di Oto Donatella Santini Maria Pia Foschini Maria Cristina Cucchi Simone Zanotti Mario Taffurelli Patrizia Nanni Pier-Luigi Lollini Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft |
| description |
Abstract We established patient-derived xenografts (PDX) from human primary breast cancers and studied whether stability or progressive events occurred during long-term in vivo passages (up to 4 years) in severely immunodeficient mice. While most PDX showed stable biomarker expression and growth phenotype, a HER2-positive PDX (PDX-BRB4) originated a subline (out of 6 studied in parallel) that progressively acquired a significantly increased tumor growth rate, resistance to cell senescence of in vitro cultures, increased stem cell marker expression and high lung metastatic ability, along with a strong decrease of BCL2 expression. RNAseq analysis of the progressed subline showed that BCL2 was connected to three main hub genes also down-regulated (CDKN2A, STAT5A and WT1). Gene expression of progressed subline suggested a partial epithelial-to-mesenchymal transition. PDX-BRB4 with its progressed subline is a preclinical model mirroring the clinical paradox of high level-BCL2 as a good prognostic factor in breast cancer. Sequential in vivo passages of PDX-BRB4 chronically treated with trastuzumab developed progressive loss of sensitivity to trastuzumab while HER2 expression and sensitivity to the pan-HER tyrosine kinase inhibitor neratinib were maintained. Long-term PDX studies, even though demanding, can originate new preclinical models, suitable to investigate the mechanisms of breast cancer progression and new therapeutic approaches. |
| format |
article |
| author |
Lorena Landuzzi Arianna Palladini Claudio Ceccarelli Sofia Asioli Giordano Nicoletti Veronica Giusti Francesca Ruzzi Marianna L. Ianzano Laura Scalambra Roberta Laranga Tania Balboni Maddalena Arigoni Martina Olivero Raffaele A. Calogero Carla De Giovanni Massimiliano Dall’Ora Enrico Di Oto Donatella Santini Maria Pia Foschini Maria Cristina Cucchi Simone Zanotti Mario Taffurelli Patrizia Nanni Pier-Luigi Lollini |
| author_facet |
Lorena Landuzzi Arianna Palladini Claudio Ceccarelli Sofia Asioli Giordano Nicoletti Veronica Giusti Francesca Ruzzi Marianna L. Ianzano Laura Scalambra Roberta Laranga Tania Balboni Maddalena Arigoni Martina Olivero Raffaele A. Calogero Carla De Giovanni Massimiliano Dall’Ora Enrico Di Oto Donatella Santini Maria Pia Foschini Maria Cristina Cucchi Simone Zanotti Mario Taffurelli Patrizia Nanni Pier-Luigi Lollini |
| author_sort |
Lorena Landuzzi |
| title |
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft |
| title_short |
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft |
| title_full |
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft |
| title_fullStr |
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft |
| title_full_unstemmed |
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft |
| title_sort |
early stability and late random tumor progression of a her2-positive primary breast cancer patient-derived xenograft |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/59a0895a37d34757859e7e9b853a7ad6 |
| work_keys_str_mv |
AT lorenalanduzzi earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT ariannapalladini earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT claudioceccarelli earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT sofiaasioli earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT giordanonicoletti earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT veronicagiusti earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT francescaruzzi earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT mariannalianzano earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT laurascalambra earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT robertalaranga earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT taniabalboni earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT maddalenaarigoni earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT martinaolivero earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT raffaeleacalogero earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT carladegiovanni earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT massimilianodallora earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT enricodioto earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT donatellasantini earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT mariapiafoschini earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT mariacristinacucchi earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT simonezanotti earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT mariotaffurelli earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT patriziananni earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft AT pierluigilollini earlystabilityandlaterandomtumorprogressionofaher2positiveprimarybreastcancerpatientderivedxenograft |
| _version_ |
1718387325980901376 |